Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aptorum Group Ltd APM

Healthcare Biotechnology
Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which... see more

Recent & Breaking News (NDAQ:APM)

Aptorum Group to Be Newly Added to MSCI HK Micro Cap Index

Business Wire May 22, 2019

Aptorum Group's Subsidiary - Claves Life Sciences Limited Establishes Novel Therapeutic Platform for Treatment of Various Diseases via Modulation of the Chemical Signaling Relating to Gut Microbiota

Business Wire May 6, 2019

UPDATE - Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM)

GlobeNewswire April 30, 2019

USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations

Business Wire April 24, 2019

Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases

Business Wire April 24, 2019

Aptorum Group's Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT(TM)

Business Wire April 24, 2019

Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019

Business Wire April 24, 2019

Aptorum Group Limited Reports 2018 Fiscal Year Financial Results and Business Update

Business Wire April 15, 2019